Yangzhou Zhongbao Pharmaceutical Co., Ltd.

To evaluate the effectiveness of different doses of suxindine sulfate injection for cardioversion in AF patients. Secondary objectives: Based on other secondary efficacy endpoints, to evaluate the effectiveness of different doses of suxindine sulfate injection for cardioversion in AF patients; to evaluate the safety of different doses of suxindine sulfate injection for cardioversion in AF patients; to evaluate the population pharmacokinetic (PopPK) characteristics of suxindine sulfate injection in AF patients; to evaluate the pharmacodynamic (PD) characteristics of suxindine sulfate injection in AF patients.

Main purpose: Taking dimenhydrinate tablets (trade name: Ningxinbao®) produced by Jiangsu Huanghe Pharmaceutical Co., Ltd. as the test preparation, according to the relevant regulations of bioequivalence testing, it will be compared with Dimenhydrinate tablets produced by Yangjindo Co., Ltd. The license holder is Yoshindo Inc.’s Dimenhydrinate Tablets (trade name: Dramamine®) as a reference preparation. The absorption speed and extent of absorption in healthy humans were compared to examine the human bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation Dimenhydrinate Tea Tablets (trade name: Ningxinbao®) and the reference preparation Dimenhydrinate Tea Tablets (trade name: Dramamine ®) in healthy subjects.

Primary objective: To evaluate the safety and tolerability of a single intravenous infusion of suxindine sulfate injection in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of a single intravenous infusion of suxindine sulfate injection in healthy Chinese subjects; to explore the pharmacodynamic (PD) characteristics of suxindine sulfate injection in healthy Chinese subjects.